Investigational drug · Phase 3
Efruxifermin
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "Efruxifermin"
First trial start
2023
Nov 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Efruxifermin", any sponsor or status.
Conditions studied
As listed on its trial records.
- NASH - Nonalcoholic Steatohepatitis
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- NASH/MASH
- NAFLD/MASLD
- NASH With Fibrosis
- MASH With Fibrosis
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Efruxifermin" as an intervention, largest first.
- A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASHPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06528314 · 2,150 participants (planned) · Start Oct 4, 2024 · Primary completion Feb 2030
Drug: Efruxifermin; Placebo · For: NASH - Nonalcoholic Steatohepatitis; MASH - Metabolic Dysfunction-Associated Steatohepatitis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 359 sites in all
- A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and FibrosisPivotal-lookingRecruiting
Akero Therapeutics, IncIndustry
NCT06215716 · 1,650 participants (planned) · Start Dec 1, 2023 · Primary completion Feb 2033
Drug: Efruxifermin; Placebo · For: NASH With Fibrosis; MASH With Fibrosis
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 361 sites in all
- A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Pivotal-lookingActive, not recruiting
Akero Therapeutics, IncIndustry
NCT06161571 · 700 participants (planned) · Start Nov 10, 2023 · Primary completion Mar 3, 2026
Drug: Efruxifermin; Placebo · For: NASH/MASH; NAFLD/MASLD
Sites: Birmingham, Alabama; Chandler, Arizona; Flagstaff, Arizona · 211 sites in all
- A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)Pivotal-lookingCompleted
Akero Therapeutics, IncIndustry
NCT05039450 · 213 participants · Start Jul 30, 2021 · Primary completion Dec 15, 2023
Drug: EFX; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Chandler, Arizona; Glendale, Arizona; Tucson, Arizona · 49 sites in all
- A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
Akero Therapeutics, IncIndustry
NCT04767529 · 128 participants · Start Feb 16, 2021 · Primary completion May 2, 2024
Drug: Efruxifermin; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Chandler, Arizona; Glendale, Arizona; Tucson, Arizona · 55 sites in all
- A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingCompleted
Akero Therapeutics, IncIndustry
NCT03976401 · 110 participants · Start May 28, 2019 · Primary completion Feb 10, 2021
Drug: EFX; Placebo · For: NASH - Nonalcoholic Steatohepatitis
Sites: Tucson, Arizona; Little Rock, Arkansas; Huntington Park, California · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The use of FGF21 analogues in MASH and MASH cirrhosis - metabolic master regulators or liver-specific mechanisms?
Holleboom AG, Schattenberg JM · JHEP Rep 2026
- MASH Cirrhosis: A Stage-Specific Framework for Care and Clinical Trial Design.
Zhang DS, Tsutsumi T, Muthiah MD · J Gastroenterol Hepatol 2026
- Untapped potential of efruxifermin in lean MASH.
Sotoudeheian M · Hepatol Int 2026
- MASLD: Established Knowledge and Emerging Directions - Guideline Updates.
Roeb E, Geier A · Z Gastroenterol 2026
- A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges.
You Z, Yang L, Long Y, et al. · Front Pharmacol 2026
- Efficacy of efruxifermin in improving liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis/nonalcoholic steatohepatitis: a systematic review and meta-analysis of randomized controlled trials.
Abideen ZU, Waseem MH, Shoaib A, et al. · Eur J Gastroenterol Hepatol 2026
Also in development for NASH - Nonalcoholic Steatohepatitis
- IVA337LanifibranorPhase 31 trial
Inventiva Pharma · NASH - Nonalcoholic Steatohepatitis
- efocipegtrutideHM15211Phase 21 trial
Hanmi Pharmaceutical Company Limited · NASH - Nonalcoholic Steatohepatitis
- SNP-610Phase 21 trial
Sinew Pharma Inc. · NASH - Nonalcoholic Steatohepatitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.